The company is a well-established enterprise in the field of genomics, with over 23 years of experience. They have completed 500+ projects in genomics and have developed over 9M lines of code. With a team of 300+ highly trained professionals, they offer solutions in precision medicine, focusing on problems related to engineering, bioinformatics, science, and translational medicine.

One significant milestone is their expertise in NGS and PCR diagnostics applications, where they accelerate the reporting of clinical NGS tests. They have extensive experience in this area, having processed tens of thousands of reports. Additionally, their genomics software application development has been a key achievement, providing tools for somatic and germline variant interpretation. The company has maintained integrity, fostered innovation, promoted collaboration, and gained a global perspective, attracting clients with high praise for their work.

Notable case studies include the successful curation of a canine database for assay design, interpretation, and reporting, aiding in the development of an oncology test. They have also achieved a 40% diagnostic yield in comprehensive neurological exome sequencing with their festiVAR tool. These projects showcase their proficiency in bioinformatics, data harmonization, and technological innovation.

Key events for the company include the Methylation Pipeline Series focusing on genomics, AI/ML applications in spatial transcriptomics, and releasing tools like festiVAR for neurological exome sequencing. They have also shared insights on genomics' role in preventive healthcare and diseases like Alzheimer's. Strand Life Sciences continues to demonstrate leadership in the field of genomics through their achievements, partnerships, and research.